Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants
about
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.The impact of "omic" and imaging technologies on assessing the host immune response to biodefence agents.Plasmodium falciparum: differential merozoite dose requirements for maximal production of various inflammatory cytokinesCharacterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussisDNA vaccines for targeting bacterial infections.TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.A safety study of a B-class CpG ODN in Sprague-Dawley rats.Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.Anti-protease and Immunomodulatory Activities of Bacteria Associated with Caribbean Sponges
P2860
Q33760871-6574215C-F4AB-4B13-8666-E493E626908BQ34275632-B4D21CBD-829C-435C-8E01-1B4BC126DF3BQ34414347-1ECA3039-48AD-42FE-9ECA-0D726CAD0DE1Q36238084-6817B8EE-6668-4401-A3B9-3224CCB4FAC9Q37384743-0B0559C0-4216-40C3-B3FD-3BA024DD16A4Q37771943-7D443ADA-A2DD-4A64-B546-FE80C7805A84Q38766473-4C132E92-22A6-4FEC-AEFC-19B2949EDEA3Q44349028-2497C96B-DFB3-4FF9-9D1E-6752F12417CBQ52777949-A007EA18-33C7-4E61-9840-16CC2D0F10ECQ57846727-30075072-E837-462E-980E-205E47D17928
P2860
Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@ast
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@en
type
label
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@ast
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@en
prefLabel
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@ast
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@en
P2093
P2860
P1433
P1476
Immunostimulatory CpG oligonuc ...... d utility as vaccine adjuvants
@en
P2093
Debra Tross
Dennis M Klinman
Hidekazu Ikeuchi
Hidekazu Shirota
Koji Tomaru
Sven Klaschik
P2860
P304
P356
10.1016/J.VACCINE.2009.10.094
P407
P577
2010-02-01T00:00:00Z